Search for Clinical Trial Results

Sponsored By

Neuromyelitis Optica - 19 Studies Found

Status Study
Enrolling by invitation Study Name: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
Condition:
  • Devic's Syndrome
  • Devic's Neuromyelitis Op
    Date: 2014-09-15
    Interventions: Biological: Autologous mesenchymal stem cells Autologous mesenchymal stem cells
NOT_YET_RECRUITING Study Name: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy
Condition:
Date: 2025-11-04
Interventions: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered.
NOT_YET_RECRUITING Study Name: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
Condition:
Date: 2025-11-04
Interventions: Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP.
Completed Study Name: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
Condition: Neuromyelitis Optica
Date: 2025-11-04
Interventions: NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladd
Completed Study Name: Pediatric NMOSD Observational Study
Condition: Neuromyelitis Optica
Date: 2025-11-04
Completed Study Name: In Vitro Study of the Biological and Immunological Activity of Imotopes� Candidates on Blood Cells of Patients With Stabilized NMO
Condition: Neuromyelitis Optica
Date: 2025-11-04
Interventions: The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interv
COMPLETED Study Name: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Condition: Neuromyelitis Optica Spectrum Disorder
Date: 2025-11-04
Interventions: IV, once every 12 weeks (Q12W)
COMPLETED Study Name: BLAZE-Limiting Approach in NMOSD
Condition: Neuromyelitis Optica Spectrum Disorders (NMOSD)
Date: 2025-11-04
Interventions: Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks
COMPLETED Study Name: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
Condition: Neuromyelitis Optica
Date: 2025-11-04
Interventions: CAR-T cells in the treatment of R/R neuromyelitis optica
<<< Previous